GENE ONLINE|News &
Opinion
Blog

WuXi Biologics Acquires Bayer’s Drug Manufacturing Facility in Wuppertal

by Tyler Chen
Share To

Following the Bayer manufacturing plant buyout in Leverkusen, Germany in January, Shanghai-based WuXi Biologics is now going to end the year with another plant acquisition from Bayer.

 

$ 183 Million Buyout

On December 21, WuXi Biologics entered into an agreement with Bayer for obtaining the Drug Substance manufacturing site at Wuppertal with a deal close to $183.3 million (€150 million). Both parties are planning on initiating a long-term sublease agreement and transition service contract.

It is the second time in 2020, WuXi Biologics gains a pharmaceutical factory in Germany.

 

The Role of Manufacturing Site in Wuppertal

MFG19 located in Wuppertal, Germany is around 30,000 square meters and equipped with 3x1000L perfusion and 6x2000L fed-batch capacity with independent downstream suites.

Purchase of MFG19 will complement the Leverkusen plant (DP7) to strengthen its supply chain to deliver more COVID-19 vaccines and other biologics. Also, MFG19 will be used for commercial manufacturing to meet the increasing demand globally.

Both procured sites are estimated to get into motion by 2021, and the transaction is expected to close in the first half of 2021.

 

About WuXi

WuXi Biologics provides a proprietary one-stop open-access biologics technology platform. It’s used to discover, develop, and manufacture biologics from concept to manufacturing.

WuXi Biologics has around 286 integrated projects by June 30. 141 projects are in the pre-clinical development stage, 125 in early-phase clinical trials, 19 projects in Phase 3 trials, and one is currently in the manufacturing stage.

By Tyler Chen

Related Article: Is Bayer’s Entry to the Gene Therapy Market Worth its Investment?

References
  1. https://www.wuxibiologics.com/News_Media-Press_Release-2020-12_21_WuXi_Biologics_to_Acquire_Drug_Substance_Facility_in_Wuppertal_Germany_from_Bayer.html
  2. https://media.bayer.com/baynews/baynews.nsf/id/Bayer-and-WuXi-Biologics-enter-into-an-agreement-on-a-Leverkusen-drug-product-plant

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Drug Promotion, Nonprescription Pathways, and Advanced Manufacturing: FDA’s Key Focus Areas in 2024 and What’s Next for 2025
2025-01-23
BIOSECURE Act Absent in Key U.S. Defense Bill—Slim Chance of Passing December 20 Resolution
2024-12-20
Bayer’s NUBEQA: Breakthrough in Prostate Cancer with 46% Risk Reduction and Future FDA Expansion Plans
2024-09-19
LATEST
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14
Health Secretary Kennedy Retracts Parts of Agency Reorganization Plan During Combative Congressional Hearing
2025-05-14
SURMOUNT-5 Trial: Zepbound Shows Greater Weight Loss Than Wegovy
2025-05-14
ASCGT Meeting Navigates Biotech Downturn After Multi-Year Slump
2025-05-14
EVENT
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top